Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions

Jaison Jacob, Debby Ngo, Nancy Finkel, Rebecca Pitts, Scott Gleim, Mark D Benson, Michelle J Keyes, Laurie A Farrell, Thomas Morgan, Lori L Jennings, Robert E Gerszten, Jaison Jacob, Debby Ngo, Nancy Finkel, Rebecca Pitts, Scott Gleim, Mark D Benson, Michelle J Keyes, Laurie A Farrell, Thomas Morgan, Lori L Jennings, Robert E Gerszten

Abstract

Background: Emerging proteomic technologies using novel affinity-based reagents allow for efficient multiplexing with high-sample throughput. To identify early biomarkers of myocardial injury, we recently applied an aptamer-based proteomic profiling platform that measures 1129 proteins to samples from patients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned myocardial injury. Here, we examined the scalability of this approach using a markedly expanded platform to study a far broader range of human proteins in the context of myocardial injury.

Methods: We applied a highly multiplexed, expanded proteomic technique that uses single-stranded DNA aptamers to assay 4783 human proteins (4137 distinct human gene targets) to derivation and validation cohorts of planned myocardial injury, individuals with spontaneous myocardial infarction, and at-risk controls.

Results: We found 376 target proteins that significantly changed in the blood after planned myocardial injury in a derivation cohort (n=20; P<1.05E-05, 1-way repeated measures analysis of variance, Bonferroni threshold). Two hundred forty-seven of these proteins were validated in an independent planned myocardial injury cohort (n=15; P<1.33E-04, 1-way repeated measures analysis of variance); >90% were directionally consistent and reached nominal significance in the validation cohort. Among the validated proteins that were increased within 1 hour after planned myocardial injury, 29 were also elevated in patients with spontaneous myocardial infarction (n=63; P<6.17E-04). Many of the novel markers identified in our study are intracellular proteins not previously identified in the peripheral circulation or have functional roles relevant to myocardial injury. For example, the cardiac LIM protein, cysteine- and glycine-rich protein 3, is thought to mediate cardiac mechanotransduction and stress responses, whereas the mitochondrial ATP synthase F0 subunit component is a vasoactive peptide on its release from cells. Last, we performed aptamer-affinity enrichment coupled with mass spectrometry to technically verify aptamer specificity for a subset of the new biomarkers.

Conclusions: Our results demonstrate the feasibility of large-scale aptamer multiplexing at a level that has not previously been reported and with sample throughput that greatly exceeds other existing proteomic methods. The expanded aptamer-based proteomic platform provides a unique opportunity for biomarker and pathway discovery after myocardial injury.

Keywords: cardiovascular disease; myocardial infarction; proteins.

© 2017 American Heart Association, Inc.

Figures

Figure 1. Protein markers that are increased…
Figure 1. Protein markers that are increased early after the onset of planned myocardial injury (PMI) and in spontaneous myocardial injury (SMI)
Data presented are from PMI derivation (PMI-D) and validation (PMI-V) cohorts of selected proteins that increased in both a) derivation (n=20) and validation (n=15) cohorts (P< 1.05E-05) and b) SMI cohorts (n=63) P < 6.17–04. P values calculated by one-way repeated measures ANOVA performed on log transformed RFU values. Edges of boxes denote 25th and 75th percentiles, lines denote median, and whiskers are plotted using Tukey method. **** P < 0.0001, *** P <0.001, ** P < 0.01; where P represents significance of change from baseline.

References

    1. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004;3:311–326.
    1. Fagerberg L, Oksvold P, Skogs M, Algenas C, Lundberg E, Ponten F, Sivertsson A, Odeberg J, Klevebring D, Kampf C, Asplund A, Sjostedt E, Al-Khalili Szigyarto C, Edqvist PH, Olsson I, Rydberg U, Hudson P, Ottosson Takanen J, Berling H, Bjorling L, Tegel H, Rockberg J, Nilsson P, Navani S, Jirstrom K, Mulder J, Schwenk JM, Zwahlen M, Hober S, Forsberg M, von Feilitzen K, Uhlen M. Contribution of antibody-based protein profiling to the human chromosome-centric proteome project (c-hpp) J Proteome Res. 2013;12:2439–2448.
    1. Ping P, Vondriska TM, Creighton CJ, Gandhi TK, Yang Z, Menon R, Kwon MS, Cho SY, Drwal G, Kellmann M, Peri S, Suresh S, Gronborg M, Molina H, Chaerkady R, Rekha B, Shet AS, Gerszten RE, Wu H, Raftery M, Wasinger V, Schulz-Knappe P, Hanash SM, Paik YK, Hancock WS, States DJ, Omenn GS, Pandey A. A functional annotation of subproteomes in human plasma. Proteomics. 2005;5:3506–3519.
    1. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB. Challenges in translating plasma proteomics from bench to bedside: Update from the nhlbi clinical proteomics programs. Am J Physiol Lung Cell Mol Physiol. 2008;295:L16–22.
    1. Juncker D, Bergeron S, Laforte V, Li H. Cross-reactivity in antibody microarrays and multiplexed sandwich assays: Shedding light on the dark side of multiplexing. Curr Opin Chem Biol. 2014;18:29–37.
    1. Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O'Sullivan JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, Carr SA, Wang TJ, Gerszten RE. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. Circulation. 2016;134:270–285.
    1. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH., 3rd Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol. 2000;36:852–855.
    1. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH., 3rd Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750–1755.
    1. Keshishian H, Burgess MW, Gillette MA, Mertins P, Clauser KR, Mani DR, Kuhn EW, Farrell LA, Gerszten RE, Carr SA. Multiplexed, quantitative workflow for sensitive biomarker discovery in plasma yields novel candidates for early myocardial injury. Molecular & cellular proteomics : MCP. 2015;14:2375–2393.
    1. Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nature biotechnology. 2011;29:635–643.
    1. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, Sabatine MS, Gerszten RE, Carr SA. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2009;8:2339–2349.
    1. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE. Metabolic signatures of exercise in human plasma. Sci Transl Med. 2010;2:33ra37.
    1. Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura H, Nishimura S, Ishii H, Sunahara N, Tanaka T. Human heart-type cytoplasmic fatty acid-binding protein (h-fabp) for the diagnosis of acute myocardial infarction. Clinical evaluation of h-fabp in comparison with myoglobin and creatine kinase isoenzyme mb. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2000;38:231–238.
    1. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clinica chimica acta; international journal of clinical chemistry. 1998;272:87–92.
    1. Collinson IR, Runswick MJ, Buchanan SK, Fearnley IM, Skehel JM, van Raaij MJ, Griffiths DE, Walker JE. Fo membrane domain of atp synthase from bovine heart mitochondria: Purification, subunit composition, and reconstitution with f1-atpase. Biochemistry. 1994;33:7971–7978.
    1. Fillgrove KL, Anderson VE. The mechanism of dienoyl-coa reduction by 2,4-dienoyl-coa reductase is stepwise: Observation of a dienolate intermediate. Biochemistry. 2001;40:12412–12421.
    1. Sun H, Li N, Wang X, Chen T, Shi L, Zhang L, Wang J, Wan T, Cao X. Molecular cloning and characterization of a novel muscle adenylosuccinate synthetase, adssl1, from human bone marrow stromal cells. Mol Cell Biochem. 2005;269:85–94.
    1. Martherus RS, Sluiter W, Timmer ED, VanHerle SJ, Smeets HJ, Ayoubi TA. Functional annotation of heart enriched mitochondrial genes gbas and chchd10 through guilt by association. Biochem Biophys Res Commun. 2010;402:203–208.
    1. Wang X, Li Q, Adhikari N, Hall JL. A role for muscle lim protein (mlp) in vascular remodeling. Journal of molecular and cellular cardiology. 2006;40:503–509.
    1. Geier C, Gehmlich K, Ehler E, Hassfeld S, Perrot A, Hayess K, Cardim N, Wenzel K, Erdmann B, Krackhardt F, Posch MG, Osterziel KJ, Bublak A, Nagele H, Scheffold T, Dietz R, Chien KR, Spuler S, Furst DO, Nurnberg P, Ozcelik C. Beyond the sarcomere: Csrp3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet. 2008;17:2753–2765.
    1. Wen HY, Xia Y, Young ME, Taegtmeyer H, Kellems RE. The adenylosuccinate synthetase-1 gene is activated in the hypertrophied heart. J Cell Mol Med. 2002;6:235–243.
    1. Osanai T, Mikami K, Kitajima M, Urushizaka M, Kawasaki K, Tomisawa T, Itaki C, Noto Y, Magota K, Tomita H. Nutritional regulation of coupling factor 6, a novel vasoactive and proatherogenic peptide. Nutrition. 2017;37:74–78.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren